Qiagen (NYSE:QGEN) Shares Purchased by Northern Trust Corp

Northern Trust Corp lifted its position in Qiagen (NYSE:QGEN - Free Report) by 29.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,250,712 shares of the company's stock after buying an additional 285,265 shares during the period. Northern Trust Corp owned approximately 0.56% of Qiagen worth $55,694,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of QGEN. The Manufacturers Life Insurance Company raised its position in Qiagen by 3.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 96,482 shares of the company's stock worth $4,322,000 after acquiring an additional 2,832 shares in the last quarter. Earnest Partners LLC lifted its stake in Qiagen by 1.6% during the fourth quarter. Earnest Partners LLC now owns 4,002,489 shares of the company's stock valued at $178,231,000 after purchasing an additional 64,575 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in Qiagen during the fourth quarter worth approximately $5,645,000. Price T Rowe Associates Inc. MD grew its position in Qiagen by 23.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 142,794 shares of the company's stock worth $6,359,000 after buying an additional 27,518 shares during the last quarter. Finally, SIH Partners LLLP bought a new position in shares of Qiagen in the fourth quarter valued at $1,907,000. Institutional investors and hedge funds own 70.00% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Baird R W cut Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Redburn Atlantic downgraded Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. UBS Group decreased their target price on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Finally, Robert W. Baird boosted their price target on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $48.42.

Qiagen Trading Up 0.9 %

Qiagen stock opened at $42.54 on Thursday. Qiagen has a one year low of $37.63 and a one year high of $49.30. The company's fifty day moving average price is $40.51 and its two-hundred day moving average price is $41.73. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. The company has a market capitalization of $9.46 billion, a price-to-earnings ratio of 118.45, a PEG ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The company had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. During the same quarter last year, the firm posted $0.44 earnings per share. The company's quarterly revenue was up 5.2% compared to the same quarter last year. On average, analysts forecast that Qiagen will post 2.26 earnings per share for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.